Intestinal epithelial cell surface glycans and co-receptors

Intestinal epithelial cell surface glycans and co-receptors are complex carbohydrate structures and associated proteins located on the apical surface of enterocytes, forming a major component of the intestinal glycocalyx (NIH, 2016; Frontiers in Immunology, 2021). These molecules, which include sialic acids, heparan sulfate, and histo-blood group antigens (HBGAs), serve as essential attachment sites for numerous enteric pathogens, including Norovirus, Rotavirus, and various pathogenic bacteria like Escherichia coli (Annual Reviews, 2016; NIH, 2023). In addition to their role in pathogen docking, these glycans and their associated co-receptors, such as integrins and toll-like receptors, are vital for maintaining the physical and immunological barrier of the gut, mediating cell-cell interactions, and regulating inflammatory signaling (Mucosal Immunology, 2023). Therapeutic interventions often target these structures using decoy receptors like Human Milk Oligosaccharides (HMOs), which mimic host glycans to prevent pathogen adhesion and subsequent invasion (Food Standards Australia New Zealand, 2016). Furthermore, the modulation of these glycans by probiotics and prebiotics represents a significant strategy for treating and preventing gastrointestinal diseases, including necrotizing enterocolitis and inflammatory bowel disease, by reinforcing the mucosal barrier and dampening aberrant immune activation (Children's Mercy, 2023).

Other names

Mucosal glycansEnterocyte surface glycansIntestinal glycocalyxPathogen-binding glycansHost cell surface carbohydrates

Drugs targeting these molecules primarily act through competitive inhibition, where soluble glycan mimetics like human milk oligosaccharides (HMOs) serve as decoy receptors to block pathogen attachment to the cell surface. Additionally, certain probiotics and metabolites can modify the expression of these glycans by regulating host glycosyltransferase genes or through enzymatic modification, thereby altering the available binding sites for pathogens. These interventions also enhance the physical barrier of the gut by promoting mucin production and strengthening tight junctions.